Close Menu
October 21, 2020
Sponsored by
Roche

Target Enrichment NGS Panel Outperforms the Gold Standard for Sequence and CNV Analysis

GenomeWebinar

Head of Division of Molecular Diagnostics,
London Health Sciences Centre (LHSC)

Target enrichment has been a major driver behind the clinical adoption of next-generation sequencing (NGS) over the last decade because it simplifies analysis and provides a cost-effective method of massive parallel resequencing. It has not only replaced Sanger sequencing, but it is actively dispensing the need for parallel copy number variant (CNV) analysis using classic techniques.

In this webinar, Bekim Sadikovic of the London Health Sciences Centre will demonstrate the performance of Roche’s new KAPA Target Enrichment technology in custom gene panels.

Dr. Sadikovic’s team has streamlined a clinically validated and robust CNV detection algorithm using targeted NGS gene panel data from the Roche SeqCap EZ platform, which they have used to assess complex genomic regions, including pseudogenic DNA sequences and mitochondrial genome heteroplasmy.

In this webinar, Dr. Sadikovic will share details of his team’s evaluation of the new KAPA technology in custom gene panels, including hereditary oncology, mitochondrial disorders, and Charcot-Marie Tooth disease, by using samples previously tested in his lab.

For Research Use Only. Not for use in diagnostic purposes.

KAPA, HYPEREXOME, and SEQCAP are trademarks of Roche. All other product names and trademarks are the property of their respective owner.

Sponsored by

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.

Mar
11
Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
17
Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar
23
Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar
24
Sponsored by
Mission Bio

This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.